+86(1812)4514114 info@phcoker.com

Raw Plecanatide powder (467426-54-6)

(2 customer reviews)

Plecanatide powder is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC)……


Status: In Mass Production
Synthesized and Customized Available
Capacity: 1277kg/month

 

Description

Raw Plecanatide powder (467426-54-6) video

 

Raw Plecanatide powder (467426-54-6) Description

Plecanatide powder is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation. It is an agonist of guanylate cyclase-C, it increases intestinal transit and fluid through a buildup of cGMP.

Raw Plecanatide powder should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age.

Raw Plecanatide powder (467426-54-6) Specifications

Product Name Plecanatide powder
Chemical Name L-Leucine,L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-cysteinyl-L-αglutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-Lcysteinyl-, cyclic (4→12),(7→15)-bis(disulfide);Plecanatide Impurtiy; SP-304;
Brand Name Trulance
Drug Class Peptide
CAS Number 467426-54-6
InChIKey NSPHQWLKCGGCQR-DLJDZFDSSA-N
Molecular Formula C65H104N18O26S4
Molecular Weight 1681.887
Monoisotopic Mass 1680.625 g/mol
Melting Point  N/A
Biological Half-Life half-life (t½) cannot be calculated due to negligible systemic absorbance
Color white to off-white
Solubility  Water Solubility:0.165 mg/mL
Storage Temperature  −20°C
Application Used for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation.

 


=

References & product citations

2 reviews for Raw Plecanatide powder (467426-54-6)

  1. Phcoker

    Got melanotan II powder to test, test result show very high quality and purity!

  2. Phcoker

    Got Plecanatide powder to test, test result show very high quality and purity!

Add a review

Your email address will not be published. Required fields are marked *